Patents
US 10391094 B2: Compositions and methods for treating myelofibrosis
- Granted
- 2019-08-27
- Filed
- 2013-05-06 application 13888096
- Type
- Utility · 26 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.
Source: PVGPATDIS, file of 2026-04-10 (ipg190827.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Impact Biomedicines, Inc. 3 patents | US company or organization | Summit, NJ | IMPACT BIOMEDICINES, INC. State business registration EXACT high confidence: identical full name and state | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Arvind Jayan | Village of La Jolla, CA | 1 | PVGPATDIS, file of 2026-04-10 | |
| Janice Louise Cacace | Miami, FL | 49 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/506 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P7/00 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2019-08-21 | Correction Corrective assignment to correct the assignee's name previously recorded at reel: 042512 frame: 0179. assignor(s) hereby confirms the assignment . | TARGEGEN, INC. signed 2017-08-16 | IMPACT BIOMEDICINES, INC. SAN DIEGO, CA | 50297/562 | PASDL, file of 2026-10-15 |
| 2018-02-12 | Release of security interest Release of security interest | LIND SA LLC, AS COLLATERAL AGENT signed 2018-02-12 | IMPACT BIOMEDICINES, INC. SAN DIEGO, CA | 44904/628 | PASDL, file of 2026-10-15 |
| 2017-11-30 | Security interest Security interest Security interest | IMPACT BIOMEDICINES, INC. signed 2017-11-30 | LIND SA, LLC, AS COLLATERAL AGENT NEW YORK, NY | 44572/660 | PASDL, file of 2026-10-15 |
| 2017-05-25 | Name change Change of name | IMPACT THERAPEUTICS, INC. signed 2016-11-18 | IMPACT BIOMEDICINES, INC. SAN DIEGO, CA | 42586/643 | PASDL, file of 2026-10-15 |
| 2017-05-25 | Assignment Assignment of assignor's interest | TARGEGEN, INC. signed 2017-05-25 | IMPACT THERAPEUTICS, INC. SAN DIEGO, CA | 42512/179 | PASDL, file of 2026-10-15 |
| 2016-04-28 | Assignment Assignment of assignor's interest | JAYAN, ARVIND signed 2011-11-07 CACACE, JANICE signed 2011-11-06 | TARGEGEN, INC. BRIDGEWATER, NJ | 38567/6 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.